Details of the Drug Formulations

General Information of Drug (ID: DMNH3PG)

Drug Name
Etoposide Drug Info
Synonyms
etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Adult acute monocytic leukemia Approved [1]
Adult kidney Wilms tumor Approved [1]
Beckwith-Wiedemann syndrome Approved [1]
Childhood kidney Wilms tumor Approved [1]
Hamartoma Approved [1]
Kidney neoplasm Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Small-cell lung cancer 2C25.Y Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Testicular cancer 2C80 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Neuroblastoma 2D11.2 Investigative [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
36462
ChEBI ID
CHEBI:4911
CAS Number
33419-42-0
TTD ID
D0B7EB
VARIDT ID
DR00162
INTEDE ID
DR0669
ACDINA ID
D00258

Full List of Drug Formulations Containing This Drug

Etoposide 50 mg capsule
Company Formulation ID FDA Description
Mylan Pharamceuticals F07800 Anhydrous citric acid; Fd&c red no. 40; Fd&c blue no. 1; Ferric oxide red; Glycerin; Propylene glycol; Titanium dioxide; Gelatin; Hypromelloses; Polyethylene glycols
------------------------------------------------------------------------------------
Etoposide Phosphate eq 100mg base/vial injectable
Company Formulation ID FDA Description
E.R. Squibb & Sons L.L.C.; H2-Pharma F24243 Sodium Citrate; Dextran 40
------------------------------------------------------------------------------------

References

1 Etoposide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6815).
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075635.
4 ClinicalTrials.gov (NCT04356690) Etoposide in Patients With COVID-19 Infection. U.S. National Institutes of Health.